{"url":"https://newsforagent.com/news/2026-11-17/dharti-proteins-public-shareholding-compliance","markdown_url":"https://newsforagent.com/news/2026-11-17/dharti-proteins-public-shareholding-compliance.md","title":"Dharti Proteins Meets 25% Public Shareholding Rule","headline":"Dharti Proteins Hits 26.08% Public Holding, Clearing 25% Listing Threshold","description":"Dharti Proteins reached 26.08% public shareholding as of November 17, 2026, clearing the 25% minimum and confirming compliance to BSE under SEBI listing rules.","section":"Regulation & Approvals","published_at":"2026-11-17T04:58:30+00:00","modified_at":"2026-11-17T04:58:30+00:00","author":"News Desk","key_takeaways":["Dharti Proteins reported public shareholding of 26.08% as of November 17, 2026, above the 25% minimum.","Managing Director Jatinbhai Ramanbhai Patel signed the BSE intimation under SEBI LODR Regulations and SCRR Rule 19A.","The company allotted 75,000 bonus equity shares in a 1:1 ratio to non-promoter members, raising total shares from 5,00,000 to 5,75,000."],"companies":[{"name":"Dharti Proteins","is_primary":true,"profile_url":null,"website":"http://www.devikaproteins.com"}],"source":{"publisher":"ScanX","title":"Dharti Proteins meets 25% minimum public shareholding norm","url":"https://scanx.trade/stock-market-news/companies/dharti-proteins-meets-25-minimum-public-shareholding-norm/56435769"},"other_sources":[{"publisher":"The future of trading","url":"https://capital.com/en-int/news/beneficient-receives-nasdaq-notice-over-failure-to-meet-minimum-market"},{"publisher":"TradingView","url":"https://www.tradingview.com/news/globenewswire:49c1b6007094b:0-ramsay-sante-obtains-approval-from-the-australian-securities-exchange-for-its-foreign-exempt-listing-in-australia/"}],"tags":["Regulation & Approvals","Dharti Proteins"],"body_markdown":"Dharti Proteins Limited reported public shareholding of 26.08% as of November 17, 2026, clearing the 25% minimum public shareholding requirement. [ScanX](https://scanx.trade/stock-market-news/companies/dharti-proteins-meets-25-minimum-public-shareholding-norm/56435769) reported the compliance filing. The company notified BSE Limited under Regulation 30 and Regulation 38 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and Managing Director Jatinbhai Ramanbhai Patel signed the communication confirming the status.\n\n## Dharti Proteins Files BSE Intimation on Public Float\n\nThe 26.08% public holding exceeds the prescribed 25% threshold, and the company stated the figure is based on the latest shareholding pattern filed with the stock exchange. The filing also covers Rule 19A of the Securities Contracts (Regulation) Rules, 1957. Dharti Proteins said the compliance keeps it in good standing on listing obligations tied to public float. The company's own [announcement](http://www.devikaproteins.com) was carried in the ScanX report.\n\n## Bonus Allotment Preceded the Compliance Filing\n\nOn November 16, 2026, the board approved the allotment of 75,000 fully paid-up bonus equity shares in a 1:1 ratio to non-promoter members, ScanX reported. The allotment followed a member resolution passed at an Extra-Ordinary General Meeting on November 6, 2026, and applied to non-promoter holders on the register as of the November 13, 2026 record date. Paid-up equity share capital rose from ₹50,00,000 to ₹57,50,000, and total equity shares rose from 5,00,000 to 5,75,000 at a face value of ₹10 each.\n\nIn September 2026, Dharti Proteins raised its borrowing and investment limits to ₹5,000 crore each and appointed Mikil Vora & Associates as internal auditor for five years, ScanX reported. The board also approved MOA and AOA alterations for shareholder ratification at the AGM on September 28, 2026. In July 2026, the company reported a net loss of ₹14.28 lakh for Q1FY27, with zero revenue from operations and total expenses of ₹14.34 lakh, wider than the ₹4.60 lakh loss in the same period a year earlier, according to ScanX.\n\n## Beneficient and Ramsay Santé Face Listing Tests\n\nNasdaq notified Beneficient on November 5, 2026, that its listed securities fell below the $35 million minimum market value for 30 consecutive business days, [The future of trading](https://capital.com/en-int/news/beneficient-receives-nasdaq-notice-over-failure-to-meet-minimum-market) reported. The 180-day compliance period ends May 4, 2027, and regaining compliance requires a closing market value of at least $35 million for 10 consecutive business days. Ramsay Santé received ASX approval for a foreign exempt listing, with CDI trading starting December 1 and the distribution expected to complete on December 9, 2026, [TradingView](https://www.tradingview.com/news/globenewswire:49c1b6007094b:0-ramsay-sante-obtains-approval-from-the-australian-securities-exchange-for-its-foreign-exempt-listing-in-australia/) reported.\n\n## Dharti Proteins Shareholder Meeting Date\n\nThe MOA and AOA alterations approved by the Dharti Proteins board are set for shareholder ratification at the AGM on September 28, 2026.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}